Does the media prefer ENLV or AMPH?

In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Amphastar Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CYRX or ENLV?

In the previous week, CryoPort had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for CryoPort and 1 mentions for Enlivex Therapeutics. CryoPort's average media sentiment score of 0.34 beat Enlivex Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ENLV or LBRX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$0.55 N/A LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A

Is ENLV or LBRX more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat LB Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% LB Pharmaceuticals N/A N/A N/A

Does the media refer more to KURA or ENLV?

In the previous week, Kura Oncology had 12 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 13 mentions for Kura Oncology and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 beat Kura Oncology's score of -0.15 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Enlivex Therapeutics (ENLV) Competitors

$0.71 +0.00 (+0.59%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$0.72 +0.00 (+0.53%)

As of 04:54 AM Eastern

Compare

ENLV vs. AMPH, CYRX, ESPR, LBRX, and KURA

Should you buy Enlivex Therapeutics stock or one of its competitors? MarketBeat compares Enlivex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enlivex Therapeutics include Amphastar Pharmaceuticals (AMPH), CryoPort (CYRX), Esperion Therapeutics (ESPR), LB Pharmaceuticals (LBRX), and Kura Oncology (KURA). These companies are all part of the "pharmaceutical products" industry.

How does Enlivex Therapeutics compare to Amphastar Pharmaceuticals?

Enlivex Therapeutics (NASDAQ:ENLV) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Enlivex Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 2,210.28%. Amphastar Pharmaceuticals has a consensus target price of $24.00, indicating a potential upside of 23.78%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat Amphastar Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%

In the previous week, Amphastar Pharmaceuticals had 6 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 7 mentions for Amphastar Pharmaceuticals and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 beat Amphastar Pharmaceuticals' score of -0.03 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amphastar Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enlivex Therapeutics has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market. Comparatively, Amphastar Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

Enlivex Therapeutics has higher earnings, but lower revenue than Amphastar Pharmaceuticals. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Amphastar Pharmaceuticals	$719.89M	1.19	$98.09M	$1.66	11.68

Summary

Enlivex Therapeutics beats Amphastar Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Enlivex Therapeutics has lower revenue, but higher earnings than CryoPort. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.43	$78.30M	$1.35	11.47
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

CryoPort has a net margin of 41.57% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Enlivex Therapeutics	N/A	248.08%	206.39%

In the previous week, CryoPort had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for CryoPort and 1 mentions for Enlivex Therapeutics. CryoPort's average media sentiment score of 0.34 beat Enlivex Therapeutics' score of 0.00 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CryoPort has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

CryoPort presently has a consensus price target of $15.11, suggesting a potential downside of 2.38%. Enlivex Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 2,210.28%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

92.9% of CryoPort shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 10.1% of CryoPort shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

CryoPort beats Enlivex Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Esperion Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Enlivex Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Esperion Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Enlivex Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 2,210.28%. Esperion Therapeutics has a consensus target price of $5.54, indicating a potential upside of 75.87%. Given Enlivex Therapeutics' higher probable upside, equities analysts clearly believe Enlivex Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics has higher earnings, but lower revenue than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Esperion Therapeutics	$403.14M	2.01	-$22.68M	-$0.06	N/A

1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Enlivex Therapeutics had 1 more articles in the media than Esperion Therapeutics. MarketBeat recorded 1 mentions for Enlivex Therapeutics and 0 mentions for Esperion Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 equaled Esperion Therapeutics'average media sentiment score.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
Esperion Therapeutics	Neutral

Esperion Therapeutics has a net margin of 0.12% compared to Enlivex Therapeutics' net margin of 0.00%. Enlivex Therapeutics' return on equity of 248.08% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Esperion Therapeutics	0.12%	-0.14%	0.12%

Summary

Enlivex Therapeutics beats Esperion Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Enlivex Therapeutics compare to LB Pharmaceuticals?

Enlivex Therapeutics (NASDAQ:ENLV) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

1.0% of Enlivex Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

Enlivex Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 2,210.28%. LB Pharmaceuticals has a consensus target price of $38.40, suggesting a potential upside of 30.61%. Given Enlivex Therapeutics' higher possible upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Enlivex Therapeutics had 1 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 1 mentions for Enlivex Therapeutics and 0 mentions for LB Pharmaceuticals. Enlivex Therapeutics' average media sentiment score of 0.00 equaled LB Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
LB Pharmaceuticals	Neutral

Enlivex Therapeutics' return on equity of 248.08% beat LB Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
LB Pharmaceuticals	N/A	N/A	N/A

Summary

Enlivex Therapeutics beats LB Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Enlivex Therapeutics has lower revenue, but higher earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.26	-$278.67M	-$3.35	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

Kura Oncology presently has a consensus price target of $25.58, suggesting a potential upside of 198.87%. Enlivex Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 2,210.28%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Kura Oncology had 12 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 13 mentions for Kura Oncology and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.00 beat Kura Oncology's score of -0.15 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enlivex Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Enlivex Therapeutics' return on equity of 248.08% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Enlivex Therapeutics	N/A	248.08%	206.39%

Kura Oncology has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Kura Oncology on 11 of the 15 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENLV vs. The Competition

Export

Metric	Enlivex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$168.54M	$2.96B	$6.48B	$11.99B
Dividend Yield	N/A	1.70%	2.67%	5.58%
P/E Ratio	-1.30	17.68	23.69	23.74
Price / Sales	N/A	302.68	513.81	108.85
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	0.09	3.83	10.41	6.78
Net Income	$1.24B	$75.85M	$3.57B	$337.51M
7 Day Performance	-15.97%	-2.00%	0.28%	-2.34%
1 Month Performance	-7.25%	-5.85%	3.27%	1.88%
1 Year Performance	-24.02%	14.03%	22.25%	25.55%

Enlivex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENLV Enlivex Therapeutics	2.5408 of 5 stars	$0.71 +0.6%	$16.50 +2,210.3%	-26.2%	$168.54M	N/A	N/A	70
AMPH Amphastar Pharmaceuticals	3.6559 of 5 stars	$18.45 +0.2%	$24.50 +32.8%	-25.4%	$812.19M	$719.89M	11.11	1,976
CYRX CryoPort	3.4034 of 5 stars	$15.74 -1.6%	$14.69 -6.7%	+121.1%	$805.93M	$176.18M	11.66	1,186	Analyst Forecast Insider Trade
ESPR Esperion Therapeutics	3.5709 of 5 stars	$3.14 +0.3%	$5.54 +76.4%	+158.2%	$805.76M	$403.14M	N/A	200
LBRX LB Pharmaceuticals	1.8071 of 5 stars	$27.02 -3.6%	$38.40 +42.1%	N/A	$803.81M	N/A	N/A	16

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. AMPH, CYRX, ESPR, LBRX, and KURA

How does Enlivex Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Enlivex Therapeutics compare to CryoPort?

Summary

How does Enlivex Therapeutics compare to Esperion Therapeutics?

Summary

How does Enlivex Therapeutics compare to LB Pharmaceuticals?

Summary

How does Enlivex Therapeutics compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. AMPH, CYRX, ESPR, LBRX, and KURA

How does Enlivex Therapeutics compare to Amphastar Pharmaceuticals?

Do institutionals and insiders believe in ENLV or AMPH?

Do analysts prefer ENLV or AMPH?

Is ENLV or AMPH more profitable?

Does the media prefer ENLV or AMPH?

Which has more risk and volatility, ENLV or AMPH?

Which has stronger earnings and valuation, ENLV or AMPH?

Summary

How does Enlivex Therapeutics compare to CryoPort?

Which has stronger valuation & earnings, CYRX or ENLV?

Is CYRX or ENLV more profitable?

Does the media refer more to CYRX or ENLV?

Which has more risk and volatility, CYRX or ENLV?

Do analysts recommend CYRX or ENLV?

Do institutionals & insiders hold more shares of CYRX or ENLV?

Summary

How does Enlivex Therapeutics compare to Esperion Therapeutics?

Which has more volatility & risk, ENLV or ESPR?

Do analysts rate ENLV or ESPR?

Which has higher valuation & earnings, ENLV or ESPR?

Do insiders & institutionals believe in ENLV or ESPR?

Does the media prefer ENLV or ESPR?

Is ENLV or ESPR more profitable?

Summary

How does Enlivex Therapeutics compare to LB Pharmaceuticals?

Do insiders and institutionals have more ownership in ENLV or LBRX?

Which has stronger earnings & valuation, ENLV or LBRX?

Do analysts rate ENLV or LBRX?

Does the media prefer ENLV or LBRX?

Is ENLV or LBRX more profitable?

Summary

How does Enlivex Therapeutics compare to Kura Oncology?

Which has higher earnings & valuation, KURA or ENLV?

Do analysts recommend KURA or ENLV?

Do insiders & institutionals hold more shares of KURA or ENLV?

Does the media refer more to KURA or ENLV?

Is KURA or ENLV more profitable?

Which has more risk and volatility, KURA or ENLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools